GMFortún

GMFortún is a Spanish biotechnology company specializing in the development of advanced personalized immunotherapies for the treatment of cancer. The company focuses on the production of autologous dendritic cell vaccines, which are designed to stimulate the patient's own immune system to recognize and destroy tumor cells. GMFortún operates a state-of-the-art GMP-certified facility for the manufacturing of cell-based medicinal products. Their clinical pipeline includes programs targeting various solid tumors, including melanoma and glioblastoma, with several candidates having reached Phase 2 clinical trials. In addition to its own drug development, the company provides contract research and manufacturing services for advanced therapy medicinal products (ATMPs).